Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference
Fate Therapeutics (NASDAQ: FATE), a clinical-stage biopharmaceutical company, has announced its participation in the 2024 Cantor Global Healthcare Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Fate Therapeutics (NASDAQ: FATE), a clinical-stage biopharmaceutical company, has announced its participation in the 2024 Cantor Global Healthcare Conference. The company, which focuses on developing iPSC-derived cellular immunotherapies for cancer and autoimmune diseases, will present on Thursday, September 19, 2024, at 12:45 PM ET in New York.
Investors and interested parties can access a live webcast of the presentation through the 'Events & Presentations' section of Fate Therapeutics' website. The archived version will be available shortly after the event concludes. This conference appearance provides an opportunity for Fate Therapeutics to showcase its innovative pipeline and progress in the field of cellular immunotherapies to a global audience of healthcare professionals and investors.
Details
News Market Reaction – FATE
The recorded move for FATE in the trading session of this news was +7.49%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that the Company will present at the 2024 Cantor Global Healthcare Conference on Thursday, September 19, 2024 at 12:45 PM ET in New York, New York.
A live webcast, if recorded, of the presentation can be accessed under “Events & Presentations” in the Investors section of the Company’s website at www.fatetherapeutics.com. The archived webcast will be available on the Company’s website shortly after the event.
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived natural killer (NK) cell and T-cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
Contact:
Christina Tartaglia
Precision AQ
212.362.1200
christina.tartaglia@precisionaq.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.